A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer - Trial NCT06012435
Access comprehensive clinical trial information for NCT06012435 through Pure Global AI's free database. This Phase 3 trial is sponsored by Seagen Inc. and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 560 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Seagen Inc.
Timeline & Enrollment
Phase 3
Nov 30, 2023
Jan 31, 2029
Primary Outcome
Overall Survival (OS),Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)
Summary
This clinical trial is studying non-small cell lung cancer (NSCLC). Participants in this
 study must have cancer that has spread through their body or can't be removed with surgery.
 Participants in this study must have been treated with no more than a platinum-based
 chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable
 genomic alterations must have had no more than 2 drugs for that genomic alteration, in
 addition to platinum-based chemotherapy.
 
 This clinical trial uses an experimental drug called SGN-B6A, which is a type of antibody
 drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This
 clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has
 been approved to treat non-small cell lung cancer. It is usually given to patients who
 previously received another anticancer treatment. In this study, one group of participants
 will get SGN-B6A on Days 1 and 8 during each 21-day-cycle. A second group of participants
 will get docetaxel on Day 1 during each 21-day cycle.
 
 This study is being done to see if SGN-B6A works better than docetaxel to treat participants
 with NSCLC. This study will also test what side effects happen when participants take these
 drugs. A side effect is anything a drug does to the body besides treating the disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06012435
Non-Device Trial